NMT2 and ovarian carcinoma: Further analysis of TCGA database showed that the loss of NMT2 is also associated with poorer patient survival in acute myeloid leukemia (AML), glioma, kidney, and ovarian cancers (Additional file 1: Fig. S8), validating the importance of NMT2 in oncogenesis and patient outcome.